Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C4BPA (C4b-binding protein alpha chain) is a protein identified as a key mediator of muscle degeneration in Duchenne muscular dystrophy (DMD). It is secreted at elevated levels by pathological fibroadipogenic precursor cells (FAPs) within the dystrophic muscle environment. Recombinant C4BPA is used in research to demonstrate its potent anti-myogenic effects, which include the impairment of myotube formation, downregulation of myogenic markers, and reduction of contractile function in muscle models. Because silencing or neutralizing C4BPA has been shown to restore myogenic capacity and improve muscle differentiation, it is currently being investigated as a novel therapeutic target to preserve muscle regeneration and mitigate the fibrotic progression associated with DMD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C4BPA recombinant protein.